Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10617MR)

This product GTTS-WQ10617MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10617MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3947MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ11684MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ13039MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ10935MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ422MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 3C23K
GTTS-WQ59MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ15614MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ14307MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG-7221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW